Efficacy of rapamycin for refractory hemangioendotheliomas in Maffucci's syndrome

Journal of Clinical Oncology

Volumn 30, Issue 23, 2012, Pages

  Riou, Stephanie ^a   Morelon, Emmanuel ^b   Guibaud, Laurent ^c,d   Chotel, Franck ^c,d   Dijoud, Frederique ^c,d   Marec Berard, Perrine ^a  

^a Institut Hématologie Oncologie Pédiatrique IHOP   (France)

^b UNIVERSITÉ DE LYON   (France)

^c HOSPICES CIVILS DE LYON   (France)

^d UNIVERSITÉ LYON 1   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; RAPAMYCIN; VINBLASTINE;

ADULT; ANTIANGIOGENIC THERAPY; ARTERIOSCLEROSIS; ARTICLE; CASE REPORT; CHONDROSARCOMA; DISABILITY; DRUG EFFICACY; ENCHONDROMA; FRACTURE; HEMANGIOENDOTHELIOMA; HEMANGIOMA; HISTOPATHOLOGY; HUMAN; LIMB DEFORMITY; MALE; MYXOID CHONDROSARCOMA; OSTEOCHONDROMA; PRIORITY JOURNAL; QUESTIONNAIRE; SPINDLE CELL HEMANGIOMA; VASCULAR DISEASE;

ANTIBIOTICS, ANTINEOPLASTIC; ENCHONDROMATOSIS; HEMANGIOENDOTHELIOMA; HUMANS; MALE; SIROLIMUS; YOUNG ADULT;

EID: 84865063149     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.41.7287     Document Type: Article

References (21)

1. Gummesson C, Ward MM, Atroshi I: The shortened disabilities of the arm, shoulder and hand questionnaire (QuickDASH): Validity and reliability based on responses within the full-length DASH. BMC Musculoskelet Disord 7:44, 2006
2. Maffucci A. Di un caso encondroma ed angioma multiplo. Movimento Medico-Chirurgico, Napoli 3:399-412; 565-575, 1881
3. Zwenneke Flach H, Ginai AZ, Wolter Oosterhuis J. Best cases from the AFIP. Maffucci syndrome: Radiologic and pathologic findings. Armed Forces Institute of Pathology. Radiographics 21:1311-1316, 2001
4. Pansuriya TC, Kroon HM, Bovée JV. Enchondromatosis: Insights on the different subtypes. Int J Clin Exp Pathol 3:557-569, 2010
5. Perkins P, Weiss SW: Spindle cell hemangioendothelioma. An analysis of 78 cases with reassessment of its pathogenesis and biologic behavior. Am J Surg Pathol 20:1196-1204, 1996
6. Lewis RJ, Ketcham AS: Maffucci's syndrome: Functional and neoplastic significance. Case report and review of the literature. J Bone Joint Surg Am 55:1465-1479, 1973
7. Wassef M, Vanwijck R, Clapuyt P, et al: Tumeurs et malformations vasculaires, classification anatomopathologique et imagerie. Ann Chir Plast Esthet 51:263-281, 2006
8. Garzon MC, Enjolras O, Frieden IJ: Vascular tumors and vascular malformations: Evidence for an association. J Am Acad Dermatol 42:275-279, 2000
9. Vacca A, Iurlaro M, Ribatti D, et al: Antiangiogenesis is produced by nontoxic doses of vinblastine. Blood 94:4143-4155, 1999
10. Ribatti D, Guidolin D, Conconi MT, et al: Vinblastine inhibits the angiogenic response induced by adrenomedullin in vitro and in vivo. Oncogene 22:6458-6461, 2003
11. Mabeta P, Pepper MS: A comparative study on the anti-angiogenic effects of DNA-damaging and cytoskeletal-disrupting agents. Angiogenesis 12:81-90, 2009
12. Sehgal SN, Baker H, Vézina C: Rapamycin (AY-22, 989), a new antifungal antibiotic. II. Fermentation, isolation and characterization. J Antibiot (Tokyo) 28:727-732, 1975
13. Abraham RT, Gibbons JJ. The mammalian target of rapamycin signaling pathway: Twists and turns in the road to cancer therapy. Clin Cancer Res 2007;13:3109-3114
14. Gutiérrez-Dalmau A, Campistol JM: Kaposi's sarcoma after renal transplantation. N Engl J Med 353:846-847; author reply 846-7, 2005
15. Hidalgo M, Rowinsky EK: The rapamycin-sensitive signal transduction pathway as a target for cancer therapy. Oncogene 19:6680-6686, 2000
16. Guba M, von Breitenbuch P, Steinbauer M, et al: Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: Involvement of vascular endothelial growth factor. Nat Med 8:128-135, 2002
17. Baldo P, Cecco S, Giacomin E, et al: mTOR pathway and mTOR inhibitors as agents for cancer therapy. Curr Cancer Drug Targets 8:647-665, 2008
18. Bissler JJ, McCormack FX, Young LR, et al: Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med 358:140-151, 2008
19. Blatt J, Stavas J, Moats-Staats B, e al: Treatment of childhood kaposiform hemangioendothelioma with sirolimus. Pediatr blood cancer 55:1396-1398, 2010
20. Alberú J: Clinical insights for cancer outcomes in renal transplant patients. Transplant Proc 42:S36-S40, 2010 (9 suppl)
21. Guba M, Koehl GE, Neppl E, et al: Dosing of rapamycin is critical to achieve an optimal antiangiogenic effect against cancer. Transpl Int 18:89-94, 2005